Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interferon in relapsing-remitting multiple sclerosis.
Breastfeeding and multiple sclerosis.
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
Ethnicity and prevalence of multiple sclerosis in east London.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.
Klotho Is a Neuroprotective and Cognition-Enhancing Protein.
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Adaptive myelination from fish to man.
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Alemtuzumab benefits hard-to-treat MS patients
Personality in multiple sclerosis (MS): impact on health, psychological well-being, coping, and overall quality of life.
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.

Pages